Article date: March 2009
Atomoxetine (Strattera) is a selective noradrenaline reuptake inhibitor, authorised to treat attention-deficit/hyperactivity disorder (ADHD) as part of a comprehensive treatment regimen.
Continued case reports of possible nervous-system and psychiatric adverse effects prompted a review of data from all sources, resulting in updated information on the risk of new-onset or worsening of serious psychiatric disorders, including psychotic reactions, hallucinations, mania, and agitation. Product information for prescribers has been updated to reflect more fully the emerging safety information.
Advice for healthcare professionals includes:
- at normal doses, atomoxetine can be associated with treatment-emergent psychotic or manic symptoms (eg, hallucinations, delusional thinking, mania, or agitation) in children and adolescents without a history of psychotic illness or mania
- if such symptoms occur, consideration should be given to a possible causal role of atomoxetine and discontinuation of treatment
- it remains possible that atomoxetine might exacerbate pre-existing psychotic or manic symptoms
Article citation: Drug Safety Update March 2009, vol 2 issue 8: 4.
Published 11 December 2014